{"id":"NCT01030822","sponsor":"GlaxoSmithKline","briefTitle":"Booster and Catch-up Vaccination With Vaccine GSK1024850A","officialTitle":"Booster Vaccination With Pneumococcal Vaccine GSK1024850A in Primed Children and Catch-up Vaccination in Unprimed Children","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2010-04-02","primaryCompletion":"2011-08-19","completion":"2011-08-19","firstPosted":"2009-12-14","resultsPosted":"2017-02-28","lastUpdate":"2018-09-20"},"enrollment":282,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"PREVENTION"},"conditions":["Infections, Streptococcal"],"interventions":[{"type":"BIOLOGICAL","name":"Pneumococcal vaccine GSK1024850A","otherNames":[]},{"type":"BIOLOGICAL","name":"Pneumococcal vaccine GSK1024850A","otherNames":[]}],"arms":[{"label":"Group A","type":"EXPERIMENTAL"},{"label":"Group B","type":"EXPERIMENTAL"},{"label":"Group C","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to evaluate the immunogenicity, safety and reactogenicity of a booster dose of pneumococcal vaccine GSK1024850A administered either at 9-18 months or 15-18 months of age in children primed in primary study NCT00814710.\n\nThis study also aims to assess the persistence of antibodies induced following primary vaccination with pneumococcal vaccine GSK1024850A in primary study NCT00814710 prior to booster vaccination and following vaccination in the present study at approximately 24 months of age.\n\nThe study is also designed to evaluate the immunogenicity, safety and reactogenicity of pneumococcal vaccine GSK1024850A when administered as a catch-up vaccination (2+1) in the second year of life in children unprimed with vaccine GSK1024850A in study NCT00814710.","primaryOutcome":{"measure":"Concentrations of Antibodies Against Vaccine Pneumococcal Serotypes","timeFrame":"Prior to booster vaccination (PRE), one month after booster vaccination (Month 1) and at approximately 24 months of age: at Month 15 for Synflorix 1 Group and at Month 9 for Synflorix 2 Group (24 months of age)","effectByArm":[{"arm":"Synflorix 1 Group","deltaMin":0.37,"sd":null},{"arm":"Synflorix 2 Group","deltaMin":0.31,"sd":null}],"pValues":[]},"eligibility":{"minAge":"9 Months","sex":"ALL","healthyVolunteers":true,"inclusionCount":9,"exclusionCount":10},"locations":{"siteCount":4,"countries":["India"]},"refs":{"pmids":["25008901"],"seeAlso":["https://www.clinicalstudydatarequest.com"]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":100},"commonTop":["Pain","Fever (≥38°C)","Swelling","Irritability","Redness"]}}